Skip Page Header

Home > Report on the risk assessment of methyl 1-(2-phenylethyl)-4-[phenyl(propanoyl)amino]piperidine-4-carboxylate (carfentanil) in the framework of the Council Decision on new psychoactive substances.

European Monitoring Centre for Drugs and Drug Addiction. [EMCDDA] (2018) Report on the risk assessment of methyl 1-(2-phenylethyl)-4-[phenyl(propanoyl)amino]piperidine-4-carboxylate (carfentanil) in the framework of the Council Decision on new psychoactive substances. Luxembourg: Publications Office of the European Union. 105 p.

[img]
Preview
PDF (Risk assessment carfentanil) - Published Version
1MB

This publication presents the data and findings of the risk assessment on methyl 1-(2-phenylethyl)-4-[phenyl(propanoyl)amino]piperidine-4-carboxylate (carfentanil), carried out by the extended Scientific Committee of the EMCDDA on 7-8 November 2017. In March 2018, at its 61st regular session, the Commission on Narcotic Drugs (CND) decided to place carfentanil in Schedule I and Schedule IV of the Single Convention on Narcotic Drugs of 1961 based on a recommendation by the World Health Organization. This recommendation was substantially supported by European data provided by the EMCDDA.

Carfentanil or carfentanyl is an analog of the synthetic opioid analgesic fentanyl.

Item Type
Evidence resource
Publication Type
Report
Drug Type
New psychoactive substance
Intervention Type
AOD disorder harm reduction
Source
Date
July 2018
Pages
105 p.
Publisher
Publications Office of the European Union
Corporate Creators
European Monitoring Centre for Drugs and Drug Addiction
Place of Publication
Luxembourg
EndNote
Accession Number
HRB (Electronic Only)

Repository Staff Only: item control page